107 results
ARS
2023 FY
MYGN
Myriad Genetics, Inc.
17 Apr 24
Annual report to shareholders
4:33pm
our business on a profitable basis; risks related to our ability to achieve certain revenue growth targets and generate sufficient revenue from our … maternal blood draw during pregnancy. Also in 2023, we achieved enrollment targets for a FirstGene prospective clinical validation study. We completed
8-K
EX-99.1
MYGN
Myriad Genetics, Inc.
27 Feb 24
Results of Operations and Financial Condition
4:05pm
its business on a profitable basis; risks related to the company’s ability to achieve certain revenue growth targets and generate sufficient revenue
8-K
qvh66 s10q93ef
27 Feb 24
Results of Operations and Financial Condition
4:05pm
8-K
2n1sg c1yz
16 Jan 24
Results of Operations and Financial Condition
9:00am
8-K
EX-99.1
x7rmg9m
16 Jan 24
Results of Operations and Financial Condition
9:00am
8-K
EX-99.1
qhpttmh0alg 9w
21 Dec 23
Departure of Directors or Certain Officers
8:30am
424B5
4gdyozmf7 pjdf
13 Nov 23
Prospectus supplement for primary offering
6:02am
424B5
ljrf5y7
8 Nov 23
Prospectus supplement for primary offering
4:05pm
S-3ASR
m6s0ioa9ved
8 Nov 23
Automatic shelf registration
4:01pm
8-K
EX-99.1
glufw1c53v10c16
6 Nov 23
Results of Operations and Financial Condition
4:05pm
8-K
duyjy9f478wcnf8
6 Nov 23
Results of Operations and Financial Condition
4:05pm
8-K
qdj bj99h
11 Oct 23
Regulation FD Disclosure
9:00am
8-K
so2u40nre fetxc59nj
5 Oct 23
Departure of Directors or Certain Officers
8:30am
8-K
13cuxfat1cpa
3 Aug 23
Results of Operations and Financial Condition
4:05pm